Price
No data yet.
Social Signal Score
Analyst Ratings
5 analystsRevenue
$1.62MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Peter Luo
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 128
- Beta
- 0.56
- Country
- CN
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- -1.79
Financials
Revenue
$1.62M+238.2%Net Income
$-16.41MEBITDA
$-16.36MFree Cash Flow
$-14.91MEPS (diluted)
$-0.36Shares Outstanding (diluted)
45.30M+366.8%Operating Expenses
$17.99MCash & Debt
$127.91MRevenue by Segment (annual)
$623.9KQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $7.67M | $-17.61M | $-0.46 |
| 2024 | $103.2K | $-33.42M | $-0.95 |
| 2023 | $18.11M | $-18.95M | $-0.55 |
| 2022 | $9.29M | $-79.97M | $-2.31 |
| 2021 | $10.18M | $-73.18M | $-2.29 |
| 2020 | $480.0K | $-16.44M | $-0.59 |
| 2019 | $480.0K | $-17.29M | $-0.49 |
| 2018 | $1.51M | $-14.72M | $-1.51 |
Valuation
ADAGhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
97-3.33%Social Signal Score
Mentions (6)
- Newsglobenewswire.com·14d ago·Neutral
…in combination with anti-CTLA-4, anti-PD-1 or anti-CD137 antibodies SAN DIEGO and SUZHOU, China, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today announced that China's National Medical Products Administration (NMPA) has approved the company's investigational new drug (IND) application for ADG138, a double-masked HER2×CD3 bispecifi…
View source ↗ - Newsseekingalpha.com·20d ago·Positive
Adagene Inc. (ADAG) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Adagene Inc. (ADAG) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsglobenewswire.com·26d ago·Neutral
Adagene Announces that Third Arc Bio Has Selected First Lead Candidate under Amended Strategic Collaboration for Development of Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology Amended terms of agreement include a transition to an integrated asset and technology partnership. SAN DIEGO and SUZHOU, China, Sept.
View source ↗ - Newsglobenewswire.com·27d ago·Negative
Adagene Achieves Milestone in Collaboration with Exelixis for Advancement of SAFEbody® Antibody-Drug Conjugate Candidates SAN DIEGO and SUZHOU, China, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today announced the achievement of a milestone in its ongoing collaboration and license agreement with Exelixis, Inc. (“Exelixis”).
View source ↗ - Newsglobenewswire.com·47d ago·Neutral
Adagene to Participate in Three Upcoming Investor Conferences SAN DIEGO and SUZHOU, China, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (Nasdaq: ADAG) a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today announced that senior management will participate in three upcoming investor conferences taking place in New York, New York. 2026 Cantor Global Healthcare Conference; New York, NY – September 9-11, 2026 For…
View source ↗ - Newsglobenewswire.com·55d ago·Neutral
Adagene Reports Six Months 2026 Financial Results and Provides Corporate Updates Randomized Phase 2 trial in microsatellite stable colorectal cancer (MSS CRC) ongoing, with results expected in 1H 2027; potential registration trial expected in 2027 once recommended dose regimen has been established
View source ↗
Earnings
Wed, Mar 31(in 6 months)
Consensus estimate $-0.21 per share
Typical surprise +28.1% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 12$-0.23 vs $-0.22miss
- Wed, Apr 1$-0.07 vs $-0.28beat
- Mon, Mar 23$-0.11 vs $-0.19beat
- Tue, Aug 12$-0.23 vs $-0.32beat
- Mon, Mar 24$-0.29 vs $-0.33beat
- Thu, Jul 25$-0.31 vs $-0.41beat
Estimates and results for ADAG via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ADAG officers and directors.
- Bought
- $162k
- Sold
- —
5 trades
0 trades
- Tam Man Kinbought
- Luo Peterbought
- Do Cuong Vbought
- Luo Peterbought
- Luo Peterbought
78 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ADAG.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.